Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer

The current study was designed to investigate the safety and effectiveness of neoadjuvant therapy in patients with borderline resectable pancreatic cancer. a retrospective case control propensity score similarity. From January 2017 June 2022, data regarding 70 who had received radical resection cancer at department hepatobiliary surgery first affiliated hospital Huzhou university acquired. group consisted 35 underwent before surgery. Patients extensive surgical were included directly. effect evaluated operation serum tumor markers carcinoembryonic antigen, antigen 125 19-9 levels compared after therapy. Comparative analyses perioperative variables, postoperative pathological symptoms complications performed between both groups. Among without complete remission or progressive disease therapy, 13 cases (37.14 %) as partial response 22 (62.86 assessed stable disease. After 19-9, indexes revealed significant (all p<0.05) downward trend. There no statistically differences p>0.05) two groups type, duration, intraoperative blood loss, number requiring transfusion, stay. Neoadjuvant treatment patient’s diameters removed lymph nodes significantly less (p<0.05) than those their R0 rates greater group. substantial variation frequency (p>0.05). Preoperative for minimally can lower marker levels. Moreover, it produce specific curative impact raising risk boosting rate, which is safe appropriate.